“2024 marked a transformative year for Inozyme (INZY) as we achieved critical milestones in our ENPP1 Deficiency program that enabled us to complete enrollment in our pivotal ENERGY 3 trial and announce promising interim data in infants and young children with ENPP1 Deficiency in January 2025,” said Douglas Treco, CEO. “We are concentrating our resources on advancing INZ-701 toward potential approval in ENPP1 Deficiency. We believe this focus will allow us to most efficiently progress our lead program while building a strong foundation for future growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme price target lowered to $30 from $43 at Piper Sandler
- Inozyme price target lowered to $11 from $14 at Wells Fargo
- Inozyme price target raised to $16 from $14 at H.C. Wainwright
- Inozyme Pharma Advances with Promising Trial Results
- Inozyme announces interim data from its ENERGY 1 trial, EAP on INZ-701
Questions or Comments about the article? Write to editor@tipranks.com